Jazz Pharmaceuticals plc and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of DefitelioA ^a-1 4 , the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy.
http://ift.tt/1gTi7Cg
http://ift.tt/1gTi7Cg
No comments:
Post a Comment